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COVID-19 Lockdown and Its Adverse
Impact on Psychological Health in
Breast Cancer
Jessica Swainston*†, Bethany Chapman*†, Elizabeth A. Grunfeld and
Nazanin Derakshan
Department of Psychological Sciences, Birkbeck, University of London, London, United Kingdom
The Coronavirus disease 2019 (COVID-19) outbreak generated an unprecedented set of
emotional challenges for women diagnosed with breast cancer. In the United Kingdom
(UK), the pandemic significantly disrupted oncology services as resources were
reassigned to care for COVID-19 patients. In addition to service disruptions, many
women received a UK Government letter advising them to shield for 12-weeks. We
aimed to explore the effect of disruption to scheduled oncology services and the UK
Government shielding letter on emotional and cognitive vulnerability. A further aim was
to investigate the relationship between COVID-19 related emotional vulnerability (COVID-
EMV) and anxiety, depression and perceived cognitive function. Women diagnosed
with primary breast cancer (N = 234) completed a series of online questionnaires to
assess their cognitive and emotional wellbeing as well as their COVID-EMV. Results
indicated that disrupted oncology services had a significant impact on COVID-EMV,
anxiety and depression, with those experiencing disruptions expressing higher general
emotional vulnerability as well as COVID-EMV. Further, the UK Government letter had
a significant effect on perceived cognitive function; those who received the letter
reported poorer cognitive function. Regression analyses revealed that after allowing
for the effects of sociodemographic and clinical variables, women’s COVID-EMV
significantly predicted worse outcomes of anxiety, depression and perceived cognitive
function. Our findings indicate that concerns about COVID-19 amongst women affected
by breast cancer leads to increased risk of developing affective disorder, such as
anxiety and depression symptomatology, among this sample. We advocate the rapid
implementation of accessible interventions designed to promote emotional resilience in
the breast cancer population.
Keywords: breast cancer, COVID-19, anxiety, depression, psycho-oncology, cognition
INTRODUCTION
The coronavirus disease 2019 (COVID-19) outbreak, caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has escalated into a global pandemic at a formidable rate. Whilst
this has caused unprecedented disruption to populations globally, it is a particularly worrying time
for vulnerable groups with pre-existing health conditions, including women with a breast cancer
diagnosis. The immunosuppressant effects of cancer and its treatment (Verma et al., 2016), coupled
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with the multimorbidity that often occurs in cancer patients
(Renzi et al., 2019), suggests that those affected by breast cancer
and other cancers may be at particular risk from the impact
of COVID-19 (Zhang et al., 2020). Indeed, in the UK, recent
estimates predict approximately 18,000 excess cancer deaths over
the next 12 months as a result of the COVID-19 emergency
(Lai et al., 2020).
Additional cancer deaths may result from the direct effects of
contracting COVID-19, or the indirect effects of the pandemic on
disruption of cancer treatment services and delays in diagnosis.
Observations indicate that at the height of the emergency, across
eight hospitals in the UK, a majority of patients with cancer
or suspected cancer were not accessing healthcare services, with
major declines in chemotherapy attendances (60% reduction)
and urgent referrals for early diagnosis (76% reduction) (Lai et al.,
2020). Early diagnosis and intervention are critical factors for
survival outcomes in breast cancer. Recent data indicates that
100% of women diagnosed at Stage 1 survive their disease for
at least one year, compared to 66% diagnosed at Stage 4 (Office
for National Statistics, 2019). However, in the midst of a global
pandemic, it is understandable that individuals with ambiguous
symptoms, which may or may not reflect cancer disease, are
reluctant to seek help.
In addition to delays in breast cancer diagnosis, and disruption
of active treatment plans (e.g., chemotherapy, radiotherapy,
surgery), women in survivorship may also experience adverse
effects from the current pandemic. Once active treatment
is complete, many breast cancer survivors are still expected
to attend routine checkups, have regular scans, or yearly
mammograms, many of which have been disrupted as a
consequence of COVID-19. For those with estrogen-positive
breast cancer, treatment can extend to 10 years post-diagnosis,
with the administration of endocrine therapies, such as tamoxifen
or aromatase inhibitors, to reduce the risk of recurrence. As such,
continued access to healthcare services is important to women in
the breast cancer survivorship period.
The debilitating physical and psychological side effects of
breast cancer diagnosis, both during and after treatment, are
well documented (Härtl et al., 2010; Hagen et al., 2016). Whilst
studies indicate that emotional distress is at its most severe during
diagnosis and active treatment (Schubart et al., 2014), clinically
important distress can persist in survivorship (Carreira et al.,
2018). Long term sequela including fatigue, sleep disturbance,
joint pain and hot flushes, as well as sexual dysfunction, can
profoundly affect quality of life (Fallowfield and Jenkins, 2015).
For younger women, further stress may derive from the potential
onset of early menopause and loss of fertility caused by estrogen
depleting endocrine therapies (Gorman et al., 2010). Negative
thinking patterns are also common including ruminative health-
related thinking styles and concerns related to the fear of cancer
recurrence and one’s own mortality (Steiner et al., 2014; Thewes
et al., 2016). Neurocognitive dysfunction is a further common
problem among the breast cancer population (see Andryszak
et al., 2017; Ahles and Root, 2018 for reviews) and may be
associated with adverse mental health outcomes (Chapman et al.,
2019). Accordingly, the breast cancer population are at high-risk
for developing clinical levels of emotional distress, which can
result in affective disorders such as anxiety, depression and post-
traumatic stress disorder (PTSD; Steiner et al., 2014; Voigt et al.,
2017; Tsaras et al., 2018).
Given the unsettling nature of the COVID-19 crisis, emotional
distress symptomatology in the breast cancer population may
be exacerbated. Along with treatment disruptions, many women
living in the UK affected by breast cancer will have received a UK
Government letter categorizing them as vulnerable and outlining
a 12-week social restriction and shielding plan (Gov.UK,
2020). Recipients of the letter may include those undergoing
chemotherapy, immunotherapy or having other targeted cancer
treatments that can affect the immune system, such as protein
kinase inhibitors or PARP inhibitors. Others may have received
a letter at the discretion of their general practitioner (GP). Such
guidelines are also likely to increase social isolation and loneliness
(Holmes et al., 2020), which are independently associated with
anxiety, depression, and self-harm (Elovainio et al., 2017). It
is currently unclear how long vulnerable populations will be
affected by the impact of the COVID-19 crisis; however, the
ramifications may be severe. It follows that understanding the
impact of the COVID-19 outbreak on cognitive and emotional
health is critical to supporting the breast cancer population
moving forward.
With the above concerns in mind, the current investigation
was two-fold. First, we decided to investigate the effect of
disruption to scheduled oncology services (i.e., delayed treatment
or canceled scans) and the UK Government shielding letter
on emotional vulnerability and perceived cognitive function
in a group of women affected by primary breast cancer. We
then decided to examine the relationship between COVID-
19 related emotional vulnerability (COVID-EMV) and general
anxiety, general depression and perceived cognitive function
whilst controlling for rumination, worry, and key clinical and
sociodemographic variables. Worry, which is characterized by
uncontrollable affectively negative thoughts about the future
(Borkovec et al., 1983), and rumination, distinguished by
repetitive affectively negative thoughts (Nolen-Hoeksema et al.,
2008), are core cognitive components of clinical anxiety and
depression respectively (Beckwé et al., 2014). As such, trait
ruminative and worrisome thinking styles are key predictors
for emotional disorder (Nolen-Hoeksema, 2000; see Koster
et al., 2017 for a review). Indeed the bidirectional relationship
between cognition and emotion is well established (Pessoa,
2008), with cognitive health playing an important role in
emotional regulation and vice versa (Dolcos et al., 2019). With
this in mind, we felt that it was important to allow for the
predictive value of worry and rumination whilst assessing the
impact of COVID-EMV on anxiety, depression and perceived
cognitive function. The additive stress caused by the COVID-
19 outbreak, which may compound worrisome and ruminative
thinking patterns, may predict worse outcomes for anxiety,
depression and cognitive health in women affected by breast
cancer, who already consistently indicate cognitive and emotional
vulnerability. Accordingly, we predicted that compared to
those unaffected, women who experienced changes to their
scheduled oncology services or appointments (i.e., telephone
appointments in place of face-to-face) or who received the
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UK Government shielding letter would express higher levels
of general emotional vulnerability (i.e., anxiety and depression)
and COVID-EMV as well as a worse perceived cognitive
function. In addition, we predicted that worry and rumination
would respectively predict anxiety and depression as well
as perceived cognitive function. Finally, we predicted that
after controlling for worry, rumination and key clinical and
sociodemographic variables, COVID-EMV would significantly
predict worse outcomes for general anxiety, general depression
and perceived cognitive function.
MATERIALS AND METHODS
Design
The design was cross-sectional. Participants were asked to
complete a series of online questionnaires measuring cognitive
and emotional health and the specific impact of the COVID-19
outbreak restrictions on emotional vulnerability.
Participants
Women with a diagnosis of primary breast cancer were recruited
through voluntary sampling using advertisements placed on
support platforms including, “Building Resilience in Breast
Cancer Centre” (BRiC Centre)1. Participants could be at any
stage of diagnosis and treatment (i.e., about to start treatment,
receiving active treatment or post-treatment).
Materials
Demographic and Clinical Questionnaire
The Demographic and Clinical Questionnaire (DQ) was
developed by the researchers to collect information regarding
the participant’s breast cancer history, sociodemographic
characteristics, and history of psychological conditions (i.e.,
anxiety or depression). All information was self-reported by the
participant.
Functional Assessment of Cancer Therapy-Cognitive
Scale (Version 3)
The Functional Assessment of Cancer Therapy-Cognitive Scale
(FACT-Cog, Version 3; Wagner et al., 2009) is a highly reliable
self-report inventory composed of 37-items that measure both
perceived cognitive impairments (i.e., “My thinking has been
slow”) and perceived cognitive ability (i.e., “I have been able to
concentrate”) over the last seven days. The Fact-Cog also assesses
the impact of these cognitive changes on quality of life and the
comments that have been made by others (i.e., “other people
have told me I seemed confused”). Questions are measured on
five-point Likert scale ranging from not at all or never (0) to
several times a day or very much (5), with a total score ranging
from 0 to 148. Higher scores indicate better cognitive function
and quality of life. The Fact-Cog has been widely implemented
1The BRiC centre (http://briccentre.bbk.ac.uk/) provides an interactive psycho-
educational support platform for woman diagnosed with breast cancer in the UK.
Currently, the BRiC centre has 1,838 UK members with a diagnosis of breast
cancer.
in previous breast cancer research (Von Ah and Tallman, 2015;
Janelsins et al., 2017; Vardy et al., 2019). Analysis showed an
excellent reliability (Cronbach’s α = 0.97) in the present study.
Rumination Response Scale
The Rumination Response Scale (RRS; Treynor et al., 2003)
is a 22-item self-report questionnaire that measures the level
of depressive rumination experienced. Items are measured on
a four-point Likert scale ranging from 1 (never) to 4 (almost
always), with scores ranging from 22 to 88. A higher total
score represents a greater level of rumination. The RRS is a
highly reliable questionnaire which has previously been used
in breast cancer studies (Swainston and Derakshan, 2018). An
excellent Cronbach’s α was found in the current study (Cronbach’s
α = 0.94).
Hospital Anxiety and Depression Scale
The self-report Hospital Anxiety and Depression Scale (HADS;
Zigmond and Snaith, 1983) is a widely used scale that measures
anxiety and depression experienced over the last seven days
(Osborne et al., 2004; Gregorowitsch et al., 2019). The HADS
consists of 14-items, seven relating to anxiety symptomatology
and seven relating to depression symptomatology. All items
are measured on a four-point Likert scale from 0 to 3,
with total scores ranging from 0 to 21 for each of the
subsections. Higher scores indicating greater levels of anxiety
and/or depression. A high reliability was found in the present
study (Cronbach’s α = 0.89).
Penn State Worry Questionnaire
The Penn State Worry Questionnaire (PSWQ) (Meyer et al.,
1990) is a self-report questionnaire composed of 16 positively
or negatively phrased items that measure trait worry. Items are
measured on a five-point Likert scale ranging from 1 (“not typical
of me”) to 5 (“very typical of me”), with higher scores representing
a greater level of pathological worry (PSWQ total score ranges
from 16 to 80). The PSWQ is a reliable and valid questionnaire
which has been used in breast cancer research (Shapiro et al.,
2003; Swainston and Derakshan, 2018). An excellent Cronbach’s
α was found in the present study (Cronbach’s α = 0.94).
Modified Self-Report-Generated Charlson
Comorbidity
The modified Charlson Comorbidity Index (CCI; Charlson et al.,
1987) is composed of nine comorbidity items that identify health
conditions (i.e., diabetes) experienced by an individual at the
present time. Items are each given a weighted value (1, 2, 3, or
6) and the CCI total score is calculated from the summation
of these values (0–19). A higher score indicates more chronic
comorbidity. The CCI has been used to measure comorbidity
in women diagnosed with breast cancer (Ording et al., 2013; Fu
et al., 2015). Reliability analysis showed a Cronbach’s α (0.13).
COVID-19 Impact Questions
Twenty-four items were developed by the authors, whose
expertise lie in psycho-oncology and affective neuroscience, to
explore the impact of the COVID-19 outbreak and the restrictive
measures on women with a diagnosis of breast cancer. Five items
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assessing the impact of the outbreak on emotional wellbeing (i.e.,
“Has the COVID-19 outbreak made you feel more: (1) anxious,
(2) upset, (3) fearful than usual” or “Has the COVID-19 outbreak
made you feel less: (4) in control, or (5) less confident than
usual”) were included, with higher scores indicating a higher level
of COVID-19 generated emotional vulnerability. A composite
score derived from the five emotional vulnerability items was
formed and reliability analysis showed a Cronbach’s α = 0.892
(see Supplementary Material for item reliability, factor analysis
and COVID-EMV correlations). In addition, individual items
assessing isolation status (i.e., yes or no), the UK Government
shielding letter (i.e., yes or no) and COVID-19 disruption to
scheduled appointments (i.e., yes or no) were included. These
individual items were utilized in our study to explore the effect
of COVID-19 related disruption and restrictive measures (i.e.,
shielding letter) on women’s emotional health (anxiety and
depression).
Personal experience of COVID-19 symptoms (high
temperature/fever, continuous cough, shortness of breath,
chest pain or pressure, sore throat, sneezing or runny nose,
loss of smell and/or taste, bluish lips or face or new confusion,
or inability to arouse)3 was also independently measured. This
allowed us to examine whether COVID related symptoms had
any impact on our relationships of interest4.
Procedure
After registering an interest in the study, participants were
emailed an information document outlining the primary aim
of the research as well as a secure URL code to access the
battery of self-report questionnaires. Participants completed an
online consent form before being directed onto the DQ. This was
followed by the cognitive and emotional wellbeing questionnaires
as well as the main COVID-19 questionnaire. Upon completion
of the study, participants received a £5 gift voucher. This research
received ethical approval from the Research Ethics Committee
of the Department of Psychological Sciences and the College
Research Ethics Committee at Birkbeck College, University of
London as well as the Economic and Social Research Council.
Statistical Analysis
Statistical analyses were performed using the Statistical Package
for the Social Sciences (SPSS, version 25). Descriptive statistics
were produced for the sociodemographic characteristics, clinical
history of breast cancer and history of psychological disorders
(see Table 1). A series of 2 × 2 ANOVAs were performed
to examine the main effects of the UK Government shielding
letter and disruption to scheduled oncology services and the
interaction effect between the UK Government shielding letter
and disruption to oncology services on women’s COVID-19-
specific-emotional vulnerability (COVID-EMV) as well as their
general anxiety, depression and perceived cognitive function.
2Questionnaire available from the authors on request.
3COVID-19 symptoms were taken from the NHS and Government public
support/advise page.
4Analysis showed that excluding women who reported experiencing a COVID-19
related symptom(s) had no effect on the significance of predictors included in three
regression models. Thus, we decided to include all participants in our analyses.
TABLE 1 | Participant demographics, clinical characteristics, and
psychiatric history.
N = 234 (%)
Sociodemographic
Age Mean = 51 Years (Min = 27, Max = 78)
Education
Secondary Education 26 (11.1)
Further Education 50 (21.4)















Undertaking volunteering work 14 (6.0)
Not undertaking any form of work 48 (20.5)
Clinical – Breast Cancer History
Age at Diagnosis Mean = 47 Years (Min = 24, Max = 77)
Time Since Diagnosis Mean = 51.46 Months (Min = 0, Max = 177)
Grade
Grade 1 28 (12.0)
Grade 2 86 (36.8)




Due to Start 2 (0.9)
Other 2 (0.9)










Other (i.e., Prescribed but decided not
to take it)
10 (4.3)
Time Since Treatment Finished Mean = 38 Months
(Min = 0, Max = 140)
History of Psychological Disorders 100 (42.7)
Prescribed medication for conditions
other than cancer
49 (20.9)
aOne participant did not disclose their ethnicity, bFour participants did not disclose
their civil status. cThree participants did not state the grade of their breast cancer.
dOne participant did not disclose the treatment they received.
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Three-stage hierarchical regression analyses were performed to
investigate the relationships between COVID-EMV and three
dependent variables: general anxiety, general depression and
perceived cognitive ability after allowing for the effects of a
series of sociodemographic and clinical predictors. Model one
included six demographic and clinical factors: (1) grade, (2)
active treatment status, (3) time since diagnosis, (4) age at
diagnosis, (5) education, and (6) health co-morbidities (measured
by CCI). Measures of ruminative behavior and pathological
worry were then added in model two and COVID-EMV as a
final predictor in the last model (model three). Using analysis
of standardized residual, no outliers were found (Anxiety:
std Residual Min = -2.31, std Residual Max = 2.53, std
deviation = 0.98; Depression: std Residual Min = -2.60, std
Residual Max = 3.14, std deviation = 0.98; Perceived cognitive
function: std Residual Min = -2.73, std Residual Max = 2.57,
std deviation = 0.98). Moreover, checks for violations of
the assumptions of collinearity, independent error, normality,
homoscedasticity and linearity were also performed and all
assumptions were met.
RESULTS
Of the 234 women (mean age = 51, SD = 7.88; mean
age at diagnosis = 47, SD = 7.68) recruited to participate
in the current study, 23% (54 women) had received a UK
Government shielding letter. A total of 74 women (31.6%)
had been impacted by disruption to their scheduled oncology
services (i.e., had appointments canceled or delivered over the
phone instead of in person) (see Table 1 for demographics)
and 24 (10.3%) had received both the government letter and
experienced disruption to their schedule oncology services or
appointments. Only 35 from 234 women (15%) reported that
they had shown COVID-19 related symptoms. About 10% of
symptoms reported were a fever and/or cough. None of these
participants reported that they had been clinically diagnosed with
the virus.
Impact of Oncology Service Disruptions
and Government Shielding Letter
Four 2 × 2 ANOVA’s were conducted to examine the main
effects of the UK Government shielding letter and the impact of
disruption to oncology services and the interaction effect between
the UK Government shielding letter and disruption to oncology
services on women’s COVID-EMV as well as their anxiety,
depression and perceived cognitive function. The results showed
that disruption to scheduled oncology services had a significant
main effect on women’s COVID-EMV (F (1, 230) = 9.68,
p = 0.002), general anxiety (F (1, 230) = 5.69, p = 0.02), and
depression (F (1, 230) = 7.22, p = 0.01). In particular, women who
experienced a service disruption showed greater levels of general
emotional vulnerability and COVID-EMV (see Table 2).They
also reported poorer perceived cognitive function, however, the
effect was non-significant (p = 0.10). There was no main effect
of the UK Government shielding letter on COVID-EMV, general
anxiety and depression, however, a significant effect was found
with perceived cognitive function (F (1, 230) = 6.69, p = 0.01)
with those who received the letter reporting a worse cognitive
function (see Table 2). The interaction effect between disruption
to scheduled oncology services and UK Government shielding
letter was not significant for any of the dependent variables of
interest (all p’s > 0.05) (see Table 3).
Impact of Covid-19 Related Distress on
Emotional Vulnerability4
General Anxiety
The results (see Table 4) revealed that the demographic and
clinical factors (education, grade, active treatment status, age at
diagnosis, time since diagnosis, and health co-morbidity) entered
into step one accounted for a small 3.6% of the variance in general
anxiety. When measures of rumination and pathological worry
were added in step two an additional 52.4% (R2 change = 0.524;
F (2, 222) = 132.12, p < 0.001) of the variance was explained with
both rumination and worry functioning as predictors of general
anxiety (p < 0.001). On the final step, COVID-EMV predicted
significant variance in anxiety with an R2 (change) of 8.9% (t
(221) = 7.50, p < 0.001), with higher COVID-EMV meeting with
higher general anxiety.
Depression
The second regression analysis (see Table 5) showed that
the model with the six demographic/clinical predictors
accounted for a moderate 6.6% of the variance in women’s
general depression. Once the predictors worry and rumination
TABLE 2 | Means and standard deviations for cognitive and emotional health as well as COVID-EMV
Disruption to oncology services No disruption to oncology services Received shielding letter No shielding letter
M SD M SD M SD M SD
Cognitive Ability (FACT-Cog-Total) 82.1 29.8 90.5 28.7 78.1 29.3 90.8 28.7
General Anxiety (HADS-A) 10.4 4.6 9.1 4.4 10.3 5.0 9.3 4.3
General Depression (HADS-D) 7.8 4.4 6.4 3.8 7.7 4.3 6.6 3.9
COVID-Generated Emotional
Vulnerability (COVID-EMV)
16.4 6.2 13.7 6.6 15.6 7.2 14.2 6.4
Rumination 49.5 14.2 45.5 14.2 49.5 15.6 45.9 13.8
Pathological Worry (Penn State
Worry)
54.6 14.6 50.0 14.8 52.9 15.6 51.0 14.7
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TABLE 3 | ANOVA results using disruption to oncology services and UK Government shielding letter as predictors.
Sum of Squares df Mean Square F P
Anxiety
Intercept 15314.11 1 15314.11 774.31 0.00
Disruption to Oncology Services 112.58 1 112.58 5.69 0.02
Government Shielding Letter 27.93 1 27.93 1.41 0.24
Disruption to Oncology Services x Government Shielding Letter 42.26 1 42.26 2.14 0.15
Error 4548.91 230 19.78
Depression
Intercept 8344.03 1 8344.03 528.22 0.00
Disruption to Oncology Services 113.97 1 113.97 7.22 0.01
Government Shielding Letter 44.08 1 44.08 2.79 0.10
Disruption to Oncology Services x Government Shielding Letter 33.17 1 33.17 2.10 0.15
Error 3633.17 230 15.80
COVID-EMV
Intercept 36269.65 1 36269.65 863.77 0.00
Disruption to Oncology Services 406.42 1 406.42 9.68 0.00
Government Shielding Letter 57.05 1 57.05 1.36 0.25
Disruption to Oncology Services x Government Shielding Letter 65.3 1 65.30 1.56 0.21
Error 9657.67 230 41.99
Cognitive Function
Intercept 1086389.00 1 1086389.00 1314.69 0.00
Disruption to Oncology Services 2305.93 1 2305.93 2.79 0.10
Government Shielding Letter 5529.04 1 5529.04 6.69 0.01
Disruption to Oncology Services x Government Shielding Letter 128.20 1 128.20 0.16 0.69
Error 190059.94 230 826.35
were entered step two explained a further 33.5% of the
variance (R2 change = 0.335, F (2, 222) = 62.03, p < 0.001).
Both rumination and worry were significant predictors of
depression (p < 0.05). In the final step, COVID-EMV
added a further 3.1% in explaining general depression
after allowing for the other variables (t (221) = 3.50,
p = 0.001). Greater COVID-EMV met with a higher level
of depression. Comorbidity was also a significant predictor
on the third step.
Perceived Cognitive Function
The final regression analysis (see Table 6) showed that
the demographic/clinical predictors explained 5.4% of the
variance in perceived cognitive function. When rumination
and worry were then entered in step two an extra 21.9%
(R2 change = 0.219; (F (2, 22) = 33.52, p < 0.001) of the
variance was explained and rumination acted as a significant
predictor (p < 0.001). On the third step, COVID-EMV
predicted significant variance in cognitive function with an R2
(change) of 3.3% (t (221) = -3.25, p = 0.001) such that lower
perceived cognitive function met a higher level of COVID-EMV.
Checks for violation of assumptions using residuals showed
that assumptions of collinearity (Tolerance > 0.1, VIF < 10),
independent error (General anxiety: Durbin–Watson = 2.00;
General depression: Durbin–Watson = 2.12; Perceived cognitive
ability: Durbin–Watson = 2.05), normality and homogeneity of
variance and linearity were met for anxiety, depression, and
cognitive function.
DISCUSSION
The current study investigated the impact of the COVID-19
pandemic on cognitive and emotional health in a group of
women affected by primary breast cancer. The breast cancer
population are at high-risk for developing clinical levels of
emotional disorder due to the distressing nature of diagnosis,
treatment and long-term side effects (Carreira et al., 2018).
The COVID-19 crisis has not only disrupted oncology services
but has further required extremely vulnerable groups to follow
social shielding guidance for their protection. It follows that
such changes may prompt further distress in this population
and as such, it is imperative that the effects of COVID-19
related stress are examined. Findings firstly indicate that those
who experienced disruptions to their oncology services had
higher levels of general anxiety, depression and COVID-19
related emotional vulnerability. Further, results show that those
who received a UK Government shielding letter had worse
perceived cognitive functioning. This suggests that the indirect
consequences of COVID-19 (i.e., oncology service disruption and
behavior change requirements) has resulted in worse cognitive
and emotional health outcomes in the breast cancer population.
In line with our predictions, further exploration demonstrated
that trait worry and rumination were significant predictors of
general anxiety and depression respectively. Both rumination
and worry are defined by their intrusive and persistent nature
and as such have been identified as key cognitive predictors
of affective disorder (Nolen-Hoeksema, 2000). Similarly, they
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TABLE 4 | Hierarchical regression analyses for the predictors of general anxiety.
b SE B β t p
General Anxiety
Step 1
Constant 12.15 (5.68, 18.63) 3.29 3.70 0.00
Education −0.70 (−1.52, 0.13) 0.42 −0.11 −1.67 0.10
Grade 0.22 (−0.63, 1.06) 0.43 0.03 0.50 0.62
Active Treatment Status 1.23 (−0.58, 3.03) 0.92 0.09 1.34 0.18
Age at Diagnosis −0.05 (−0.13, 0.03) 0.04 −0.08 −1.25 0.21
Time since Diagnosis
(Months)
−0.02 (−0.04, 0.00) 0.01 −0.12 −1.76 0.08
Co-morbidity 0.15 (−0.49, 0.79) 0.32 0.03 0.46 0.65
Step 2
Constant −1.27 (−5.97, 3.44) 2.39 −0.53 0.60
Education −0.43 (−0.99, 0.13) 0.28 −0.07 −1.50 0.14
Grade −0.1 (−0.68, 0.48) 0.29 0.06 −0.35 0.73
Active Treatment Status 0.02 (−1.23, 1.26) 0.63 0.00 0.02 0.98
Age at Diagnosis −0.01 (−0.07, 0.04) 0.03 −0.03 −0.53 0.59
Time since Diagnosis
(Months)
0.01(−0.01, 0.02) 0.01 0.04 0.84 0.40
Co-morbidity 0.08 (−0.36, 0.51) 0.22 0.02 0.34 0.74
Rumination 0.13 (0.10, 0.16) 0.02 0.42 7.60 0.00
Pathological Worry 0.13 (0.10, 0.16) 0.02 0.44 8.31 0.00
Step 3
Constant −2.15 (−6.37, 2.07) 2.41 −1.01 0.32
Education −0.40 (−0.90, 0.10) 0.25 −0.06 −1.57 0.12
Grade −0.11 (−0.62, 0.41) 0.26 −0.02 −0.40 0.69
Active Treatment Status 0.62 (−0.51, 1.74) 0.57 0.05 1.08 0.28
Age at Diagnosis −0.02 (−0.07, 0.03) 0.02 −0.03 −0.76 0.45
Time since Diagnosis
(Months)
0.01 (0.00, 0.02) 0.01 0.08 1.89 0.06
Co-morbidity 0.16 (−0.23, 0.55) 0.20 0.03 0.83 0.41
Rumination 0.09 (0.06, 0.12) 0.02 0.28 5.35 0.00
Pathological Worry 0.08 (0.05, 0.11) 0.02 0.27 5.24 0.00
COVID-EMV 0.28 (0.20, 0.35) 0.04 0.41 7.50 0.00
95% Confidence Intervals.
have further been associated with deficits in cognitive efficiency
(Beckwé et al., 2014; see Koster et al., 2017 for a review).
Supporting this, we found that rumination was a significant
predictor of worse perceived cognitive function. Of further
pertinence, findings indicate that comorbidity with other health
conditions significantly predicted higher levels of depression and
worse cognitive functioning. This corroborates current reviews
that point to the detrimental effects of multimorbidity on
psychological health, with studies indicating that depression is
two to three times more likely in individuals with multiple health
conditions (Read et al., 2017). Finally, of critical importance,
after controlling for the predictive value of all demographic
variables, multimorbidity as well as worry and rumination,
findings demonstrated that COVID-19 related emotional distress
was a significant predictor for worse outcomes of anxiety,
depression and perceived cognitive function. This suggests
that the restrictions relating to the COVID-19 pandemic has
emphasized pre-existing levels of cognitive and emotional
vulnerability in women affected by primary breast cancer.
TABLE 5 | Hierarchical regression analyses for the predictors of
general depression.
b SE B β t p
General Depression
Step 1
Constant 10.83 (5.08, 16.59) 2.92 3.71 0.00
Education −0.42 (−1.15, 0.31) 0.37 −0.07 −1.13 0.26
Grade 0.65 (−0.10, 1.40) 0.38 0.11 1.70 0.09
Active Treatment Status −0.13 (−1.73, 1.48) 0.81 −0.01 −0.16 0.88
Age at Diagnosis −0.07 (−0.14, 0.00) 0.04 −0.12 −1.87 0.06
Time since Diagnosis
(Months)
−0.02 (−0.04, −0.00) 0.01 −0.17 −2.51 0.01
Co-morbidity 0.65 (0.08, 1.21) 0.29 0.15 2.24 0.03
Step 2
Constant 2.18 (−2.78, 7.13) 2.51 0.87 0.39
Education −0.25 (−0.84, 0.34) 0.30 −0.04 −0.82 0.41
Grade 0.33 (−0.28, 0.94) 0.31 0.06 1.07 0.29
Active Treatment Status −1.23 (−2.54, 0.08) 0.67 −0.10 −1.85 0.07
Age at Diagnosis −0.04 (−0.10, 0.01) 0.03 −0.08 −1.48 0.14
Time since Diagnosis
(Months)
−0.00 (−0.02, 0.01) 0.01 −0.02 −0.32 0.75
Co-morbidity 0.53 (0.08, 0.99) 0.23 0.12 2.30 0.02
Rumination 0.14 (0.10, 0.18) 0.02 0.49 7.72 0.00
Pathological Worry 0.05 (0.01, 0.08) 0.02 0.18 2.84 0.01
Step 3
Constant 1.70 (−3.14, 6.54) 2.46 0.69 0.49
Education −0.23 (−0.81, 0.36) 0.29 −0.04 −0.79 0.43
Grade 0.33 (−0.27, 0.92) 0.30 0.06 1.09 0.28
Active Treatment Status −0.91 (−2.20, 0.38) 0.66 −0.07 −1.39 0.17
Age at Diagnosis −0.04 (−0.10, 0.01) 0.03 −0.08 −1.59 0.11
Time since Diagnosis
(Months)
0.00 (−0.01, 0.01) 0.01 0.01 0.13 0.90
Co-morbidity 0.58 (0.14, 1.03) 0.23 0.14 2.56 0.01
Rumination 0.12 (0.08, 0.15) 0.02 0.41 6.20 0.00
Pathological Worry 0.02 (−0.02, 0.06) 0.02 0.08 1.16 0.25
COVID-EMV 0.15 (0.07, 0.23) 0.04 0.24 3.50 0.00
95% Confidence Intervals.
Pertinently, our analyses controled for potential confounding
effects of clinical variables including active treatment status,
grade of breast cancer, age of diagnosis, and time since diagnosis.
This therefore suggests that findings are applicable to women
affected by breast cancer at varying disease and treatment
stages, and not only those with more severe cancer-specific
vulnerabilities. In the same way, our analyses controlled for
the influential effects of trait worry and rumination, which in
line with current research, we would typically expect to predict
anxiety and depression. Findings indicate that once the predictive
value of worry and rumination have been accounted for, COVID-
19 related distress was still predictive of generalized anxiety and
depression. This suggests that the emotional stress experienced
by women affected by breast cancer is over and above pre-
existing levels as a result of the restrictions relating to COVID-19.
Considering that psychological distress is already established as
a common component of the breast cancer experience (Carreira
et al., 2018), this findings has important implications. Moreover,
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TABLE 6 | Hierarchical regression analyses for the predictors of perceived
cognitive function.




Constant 93.04 (51.05, 135.04) 21.31 4.37 0.00
Education 2.38 (−2.96, 7.72) 2.71 0.06 0.88 0.38
Grade −5.66 (−11.15, −0.18) 2.78 −0.13 −2.04 0.04
Active Treatment Status −8.83 (−20.55, 2.88) 5.95 −0.10 −1.49 0.14
Age at Diagnosis 0.31 (−0.20, 0.82) 0.26 0.08 1.21 0.23
Time since Diagnosis
(Months)
0.10 (−0.02, 0.22) 0.06 0.11 1.65 0.10
Co-morbidity −3.87 (−8.01, 0.27) 2.10 −0.12 −1.84 0.07
Step 2
Constant 138.18 (98.62, 177.74) 20.08 6.88 0.00
Education 1.46 (−3.25, 6.17) 2.39 0.04 0.61 0.54
Grade −3.55 (−8.41, 1.32) 2.47 −0.08 −1.44 0.15
Active Treatment Status −1.78 (−12.26, 8.70) 5.32 −0.02 −0.34 0.74
Age at Diagnosis 0.18 (−0.27, 0.63) 0.23 0.05 0.80 0.43
Time since Diagnosis
(Months)
−0.02 (−0.12, 0.09) 0.06 −0.02 −0.28 0.78
Co-morbidity −3.04 (−6.69, 0.62) 1.86 −0.01 −1.64 0.10
Rumination −0.95 (−1.24, −0.67) 0.14 −0.46 −6.60 0.00
Pathological Worry −0.09 (−0.36, 0.17) 0.13 −0.05 −0.70 0.48
Step 3
Constant 141.70 (102.91, 180.50) 19.69 7.20 0.00
Education 1.35 (−3.26, 5.97) 2.34 0.03 0.58 0.56
Grade −3.53 (−8.30, 1.23) 2.42 −0.08 −1.46 0.15
Active Treatment Status −4.17(−14.53, 6.19) 5.26 −0.05 −0.79 0.43
Age at Diagnosis 0.20 (−0.24, 0.64) 0.22 0.05 0.89 0.38
Time since Diagnosis
(Months)
−0.04 (−0.15, 0.07) 0.05 −0.04 −0.70 0.48
Co-morbidity −3.39 (−6.98, 0.20) 1.82 −0.11 −1.86 0.06
Rumination −0.78 (−1.08, −0.49) 0.15 −0.38 −5.19 0.00
Pathological Worry 0.10 (−0.8, 0.40) 0.14 0.05 0.73 0.47
COVID-EMV −1.10 (−1.77, −0.43) 0.34 −0.25 −3.25 0.00
95% Confidence Intervals.
emotional distress in women affected by breast cancer has been
associated with reduced treatment compliance (Greer et al.,
2008), which may influence disease progression and mortality
(Satin et al., 2009). Accordingly, any additional distress brought
about the COVID-19 pandemic is a noteworthy concern for this
population. Furthermore, cancer-related cognitive impairment is
a common component of the breast cancer experience (Ahles and
Root, 2018), which can greatly impact quality of life. As such,
elevated levels of cognitive inefficiency may have considerable
consequences for everyday functioning in this population. That
said, the above findings must be interpreted with caution. Whilst
results show COVID-EMV predicts worse levels of anxiety,
depression and cognitive functioning, the relationship may be
bidirectional. That is, worse anxiety, depression and cognitive
functioning may also predict greater levels of COVID-EMV.
Similarly, there may still be a third variable not controlled for in
the current analyses, which may have influenced our outcomes.
Overall, the current findings corroborate and add to recent
research which suggests that vulnerable groups with pre-existing
health conditions, such as those with a breast cancer diagnosis,
are likely to suffer worse outcomes as a result of the COVID-19
pandemic (Lai et al., 2020; Zhang et al., 2020). Cancer patients
can experience longer term immunosuppressant effects of cancer
and its treatment (Kang et al., 2009; Verma et al., 2016), and
are further likely to experience multimorbidity with other
health conditions (Renzi et al., 2019). As such, the additional
indirect effects of treatment delays and disruptions may lead to a
significant increase in the psychological burden associated with
breast cancer. Further longitudinal research is now required to
assess the extent of continued distress associated with COVID-19
disruptions. We advocate that future government preparedness
plans consider the mental health implications of pandemics
for this population. As such, appropriate eHealth interventions
that can be delivered remotely should be further developed
and implemented (Penedo et al., 2020). Capitalizing on recent
research promoting the effectiveness of online interventions
for anxiety and depression in breast cancer may facilitate
this aim (Swainston and Derakshan, 2018). As the pandemic
progresses, the mental health effects of COVID-19 may be
further amplified by longer term effects such as economic
recession and continued isolation for vulnerable groups (Gunnell
et al., 2020; Holmes et al., 2020). We therefore recommend the
continued scientific investigation of COVID-19 related distress
in the breast cancer population to identify long-term cognitive
and emotional outcomes.
Limitations
The current study was limited in its scope. As a consequence
of shielding and social distancing, participants were recruited
via social media platforms and therefore may not be fully
representative of the breast cancer population at large. Similarly,
our sample lacked diversity; the majority of our participants
were caucasian and well-educated. This means that other breast
cancer groups, such as those from BAME populations, may be
underrepresented in the current study. Emerging data suggests
that BAME populations are at increased risk of acquiring
the SARS-Cov-2 infection compared to white individuals, and
additionally suffer worse clinical outcomes (Pan et al., 2020). As
such, we can speculate that increased psychological burden may
be even further emphasized in BAME populations. In addition,
the UK Government letter categorizing women as vulnerable
was sometimes issued at the discretion of the participant’s GP.
This means that this group may have had varying degrees
of vulnerability. Finally, due to the cross-sectional design of
our study, we were unable to measure levels of cognitive
and emotional vulnerability pre-pandemic, and as such cannot
measure to what extent emotional vulnerability has increased.
CONCLUSION
The current study investigated the impact of the COVID-19
outbreak on cognitive and emotional health in breast cancer.
Findings suggest that the breast cancer population are at an
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increased risk of developing psychological disorder during the
COVID-19 pandemic. This has critical implications for pandemic
preparedness plans, which should consider such consequences. It
further highlights the importance of mental health interventions
that can be delivered remotely. Future longitudinal research
should continue to monitor the longer-term effects of COVID-19
on psychological health in breast cancer.
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